Ayala Pharmaceuticals, Inc. (ADXS)

Market Cap	1.04M
Revenue (ttm)	13.00K
Net Income (ttm)	-48.07M
Shares Out	49.30M
EPS (ttm)	-7.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Open	0.0210
Previous Close	0.0201
Day's Range	0.0210 - 0.0210
52-Week Range	0.0012 - 1.4900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2024

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Kenneth Berlin
• Employees: 21
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADXS